Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients

Hepatology

Volumn 56, Issue 1, 2012, Pages 17-27

  Rasmussen, Angela L ^a   Tchitchek, Nicolas ^b   Susnow, Nathan J ^c,d   Krasnoselsky, Alexei L ^a   Diamond, Deborah L ^a   Yeh, Matthew M ^a   Proll, Sean C ^a   Korth, Marcus J ^a   Walters, Kathie Anne ^a,e   Lederer, Sharon ^a   Larson, Anne M ^c,f   Carithers, Robert L ^c   Benecke, Arndt ^b   Katze, Michael G ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CNRS   (France)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d Meriter Medical Group   (United States)

^e INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER; LIVER BIOPSY; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER FAILURE; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TISSUE DONORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84863508882     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25612     Document Type: Article

References (29)

1. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. HEPATOLOGY 2000; 32: 852-858.
2. Rowe IA, Barber KM, Birch R, Curnow E, Neuberger JM. Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource? World J Gastroenterol 2010; 16: 5070-5076.
3. Asaoka T, Kato T, Marubashi S, Dono K, Hama N, Takahashi H, et al. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl 2009; 15: 1738-1749.
4. Smith MW, Walters KA, Korth MJ, Fitzgibbon M, Proll S, Thompson JC, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006; 130: 179-187.
5. Mas V, Maluf D, Archer KJ, Potter A, Suh J, Gehrau R, et al. Transcriptome at the time of HCV recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transpl 2011; 17: 825-835.
6. Becavin C, Tchitchek N, Mintsa-Eya C, Lesne A, Benecke A. Improving the efficiency of multidimensional scaling in the analysis of high-dimensional data using singular value decomposition. Bioinformatics 2011; 27: 1413-1421.
7. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009; 119: 3544-3555.
8. Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze MG. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog 2009; 5: e1000269.
9. Blackham S, Baillie A, Al-Hababi F, Remlinger K, You S, Hamatake R, McGarvey MJ. Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. J Virol 2010; 84: 5404-5414.
10. Ramirez S, Perez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008; 14( Suppl 2): S27-S35.
11. Watanabe N, Aizaki H, Matsuura T, Kojima S, Wakita T, Suzuki T. Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules. Biochem Biophys Res Commun 2011; 407: 135-140.
12. Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, Proll SC, et al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 2010; 6: e1000719.
13. Lloyd SP. Least-Squares Quantization in PCM. IEEE Transactions Information Theory 1982; 28: 129-137.
14. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002; 8: 814-821.
15. Gehrau R, Maluf D, Archer K, Stravitz R, Suh J, Le N, Mas V. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med 2011; 17: 824-833.
16. Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011; 31: 443-460.
17. Schmidt J, Neumann-Haefelin C, Altay T, Gostick E, Price DA, Lohmann V, et al. Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency. J Virol 2011; 85: 5232-5236.
18. Schmidt J, Thimme R, Neumann-Haefelin C. Host genetics in immune-mediated hepatitis C virus clearance. Biomark Med 2011; 5: 155-169.
19. Kriegs M, Burckstummer T, Himmelsbach K, Bruns M, Frelin L, Ahlen G, et al. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 2009; 284: 28343-28351.
20. Sene D, Levasseur F, Abel M, Lambert M, Camous X, Hernandez C, et al. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog 2010; 6: e1001184.
21. Johnson CL, Owen DM, Gale MJr., Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 2007; 282: 10792-10803.
22. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102: 2992-2997.
23. Testino G, Sumberaz A, Ansaldi F, Borro P, Leone S, Ancarani AO, et al. Treatment of recurrent hepatitis C (genotype 1) with pegylated interferon alfa-2b and ribavirin combination and maintenance therapy. Hepatogastroenterology 2011; 58: 536-538.
24. Denard B, Seemann J, Chen Q, Gay A, Huang H, Chen Y, Ye J. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell Host Microbe 2011; 10: 65-74.
25. Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 2011; 85: 7989-8001.
26. Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif 2011; 44: 291-299.
27. Chui YL, Ching AK, Chen S, Yip FP, Rowlands DK, James AE, et al. BRE over-expression promotes growth of hepatocellular carcinoma. Biochem Biophys Res Commun 2010; 391: 1522-1525.
28. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, ed. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005: 397-420.
29. Noth S, Brysbaert G, Benecke A. Normalization using weighted negative second order exponential error functions (NeONORM) provides robustness against asymmetries in comparative transcriptome profiles and avoids false calls. Genomics Proteomics Bioinformatics 2006; 4: 90-109.